A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.
暂无分享,去创建一个
Michael Proschan | Lori E Dodd | Jerome Pierson | H Clifford Lane | Jean-Jacques Muyembe-Tamfum | Lisa Hensley | Elizabeth Higgs | Ian Crozier | Adam C Levine | Kelly Cahill | Tyler Bonnett | M. Proschan | L. Dodd | R. Davey | H. Lane | J. Ledgerwood | R. Grais | L. Hensley | A. Levine | E. Higgs | J. Muyembé-Tamfum | J. Aboulhab | Tyler Bonnett | S. Mulangu | S. Sivapalasingam | Olivier Tshiani Mbaya | Daniel Mukadi | Mariano Lusakibanza Manzo | Didier Nzolo | Antoine Tshomba Oloma | A. Ibanda | Rosine Ali | S. Coulibaly | Janet V. Diaz | Billy Sivahera | Modet Camara | R. Kojan | R. Walker | Bonnie Dighero-kemp | H. Cao | Philippe Mukumbayi | P. Mbala-Kingebeni | S. Ahuka | Sara Albert | Ian Crozier | Michael Duvenhage | C. Proffitt | M. Teitelbaum | T. Moench | K. Barrett | K. Cahill | Katherine Cone | R. Eckes | B. Herpin | J. Pierson | M. Smolskis | Ydrissa Sow | J. Tierney | Wendy Holman | Nikki Gettinger | D. Vallée | Jacqueline Nordwall | Thomas Moench | Sumathi Sivapalasingam | Rebecca Grais | Richard T Davey | Richard Kojan | Robert Walker | Sabue Mulangu | Huyen Cao | Didier Nzolo | Placide Mbala-Kingebeni | Daniel Mukadi | Julie Ledgerwood | Betsey Herpin | Kevin Barrett | John Tierney | Olivier Tshiani Mbaya | Mariano Lusakibanza Manzo | Antoine Tshomba Oloma | Augustin Ibanda | Rosine Ali | Sinaré Coulibaly | Janet Diaz | Billy Sivahera | Modet Camara | Bonnie Dighero-Kemp | Philippe Mukumbayi | Steve Ahuka | Sarah Albert | Michael Duvenhage | Calvin Proffitt | Marc Teitelbaum | Jamila Aboulhab | Katherine Cone | Risa Eckes | Mary Smolskis | Ydrissa Sow | Wendy Holman | Nikki Gettinger | David Vallée | Jacqueline Nordwall | Janet Diaz | J. Muyembe‐Tamfum | J. Nordwall | S. Albert | Kelly Cahill | Placide Mbala-Kingebeni | W. Holman
[1] S. Sivapalasingam,et al. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study. , 2018, The Lancet. Infectious diseases.
[2] J. Mascola,et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody , 2016, Science.
[3] Jay B. Varkey,et al. Successful delivery of RRT in Ebola virus disease. , 2015, Journal of the American Society of Nephrology : JASN.
[4] Y. Sakurai,et al. Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates , 2018, The Journal of infectious diseases.
[5] J. Mascola,et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study , 2019, The Lancet.
[6] U. S. Department of Health and Human Services FDA Cen Research,et al. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.
[7] Jeffrey R. Kugelman,et al. Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment. , 2019, The Lancet. Infectious diseases.
[8] A. Sanchez,et al. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. , 2007, The Journal of infectious diseases.
[9] M. Fay,et al. Combining one‐sample confidence procedures for inference in the two‐sample case , 2015, Biometrics.
[10] William A. Lee,et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.
[11] Michael A Proschan,et al. Statistical considerations for a trial of Ebola virus disease therapeutics , 2016, Clinical trials.
[12] J. Strong,et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ , 2014, Nature.